Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2394669 | 0.92 | MAPT (0.33) | MAPTOPRK1 | |
| SCHEMBL1725753 | 0.83 | MAPT (0.35) | MAPTLMNATP53RXFP1MEN1 | |
| SCHEMBL2392634 | 0.83 | MAPT (0.37) | MAPTLMNATP53RXFP1MEN1 | |
| SCHEMBL2397981 | 0.83 | MAPT (0.37) | MAPTLMNATP53RXFP1MEN1 | |
| SCHEMBL2394672 | 0.81 | MAPT (0.32) | MAPT | |
| SCHEMBL2392517 | 0.80 | RAB9A (0.38) | — | |
| SCHEMBL1724738 | 0.80 | MAPK14 (0.39) | — | |
| SCHEMBL12259614 | 0.79 | BRD4 (0.43) | MAPTTP53RXFP1MEN1ALDH1A1 | |
| SCHEMBL12259615 | 0.79 | BRD4 (0.43) | MAPTTP53RXFP1MEN1ALDH1A1 | |
| SCHEMBL2390183 | 0.78 | TGM2 (0.36) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012980-B2 | Isoquinolinone derivatives | ASTRAZENECA AB (SE) | 2011-09-06 | — | — | US | disclosed |
| US-20100099665-A1 | ISOQUINOLINONE DERIVATIVES | ASTRAZENECA AB (SE) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099665-A1 | ISOQUINOLINONE DERIVATIVES | SDHA, NQO1, CYP3A5 | MAPT 955/4885OPRK1 282/4885LMNA 1339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.